~~<i id='F80EF23B22'><strike id='F80EF23B22'><tt id='F80EF23B22'><pre id='F80EF23B22'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：fashion 2025-09-06 01:58:03 - browse：22

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Congress extends some pandemic preparedness programs

knowledge

entertainment

focus

leisure time

hotspot

DrewWeissman(left)andKatalinKarikó,whoselongtimepartnershipwasrecognizedwithaNobelPrizeonMonday.Pegg

WSS

Nobel honors Karikó and Weissman's enduring partnership

'The View' co

EMA weighs against approval for Mirati's lung cancer drug

Lawsuit highlights wrinkle for disputes over surprise medical bills

How Brent Saunders' Allergan experiment failed

Medicare innovation center doesn’t save money, experts say

hotspot

Wikipedia

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

'The View' co

As demand for Covid shots wanes, Moderna seeks its next success

Why Marc Tessier

Guidelines to prevent youth baseball injuries need more muscle

Why Marc Tessier

Medical leaders decry Supreme Court decision on affirmative action

Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation

New air purifier tech could be key to improving indoor air quality

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

entertainment

What will Novo Nordisk's VC do with its influx of cash?

The biotech scorecard for Q4: 16 stock

CRISPR base editing slashes cholesterol levels in monkeys

New chief aims to remake Sanofi Genzyme

Study points to new risk in gene therapy death of Terry Horgan

EMA weighs against approval for Mirati's lung cancer drug

focus

focus

leisure time

hotspot